Sequoia Financial Advisors LLC Raises Stock Position in Danaher Corporation $DHR

Sequoia Financial Advisors LLC lifted its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 9.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 21,644 shares of the conglomerate's stock after purchasing an additional 1,909 shares during the period. Sequoia Financial Advisors LLC's holdings in Danaher were worth $4,276,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. Nuveen LLC acquired a new position in shares of Danaher during the first quarter worth about $833,941,000. Invesco Ltd. raised its holdings in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. raised its holdings in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP increased its holdings in Danaher by 33.2% in the first quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock valued at $651,515,000 after buying an additional 791,662 shares during the last quarter. Finally, Parnassus Investments LLC lifted its stake in Danaher by 23.3% during the first quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock worth $784,745,000 after purchasing an additional 722,636 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on DHR. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Rothschild & Co Redburn reiterated a "neutral" rating and set a $220.00 price target (down previously from $245.00) on shares of Danaher in a research note on Wednesday, October 8th. Bank of America reduced their target price on shares of Danaher from $230.00 to $220.00 and set a "buy" rating for the company in a report on Monday, September 22nd. Guggenheim reaffirmed a "buy" rating and issued a $250.00 target price on shares of Danaher in a report on Wednesday, July 23rd. Finally, Redburn Partners set a $220.00 price target on Danaher in a research report on Wednesday, October 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $244.60.

Insider Activity

In related news, Director Teri List sold 2,778 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.20% of the stock is owned by corporate insiders.

Danaher Stock Performance

NYSE:DHR opened at $206.19 on Wednesday. The stock has a market cap of $147.64 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.92 and a beta of 0.77. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $279.41. The firm's fifty day simple moving average is $200.96 and its 200-day simple moving average is $197.13. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same period last year, the firm earned $1.72 EPS. The company's revenue for the quarter was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.